Baqsimi

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Shusha Taarifa za kipeperushi (PIL)
05-07-2021
Shusha Tabia za bidhaa (SPC)
05-07-2021

Viambatanisho vya kazi:

Glucagon

Inapatikana kutoka:

Eli Lilly Nederland B.V.

ATC kanuni:

H04AA01

INN (Jina la Kimataifa):

glucagon

Kundi la matibabu:

Pancreatic hormones, Glycogenolytic hormones

Eneo la matibabu:

Diabetes Mellitus

Matibabu dalili:

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Bidhaa muhtasari:

Revision: 1

Idhini hali ya:

Authorised

Idhini ya tarehe:

2019-12-16

Taarifa za kipeperushi

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BAQSIMI 3 MG NASAL POWDER IN SINGLE-DOSE CONTAINER
glucagon
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Baqsimi is and what it is used for
2.
What you need to know before you are given Baqsimi
3.
How Baqsimi is given
4.
Possible side effects
5.
How to store Baqsimi
6.
Contents of the pack and other information
1.
WHAT BAQSIMI IS AND WHAT IT IS USED FOR
Baqsimi contains the active substance glucagon, which belongs to a
group of medicines called
glycogenolytic hormones. It is used to treat severe hypoglycaemia
(very low blood sugar) in people
with diabetes. It is for use in adults, adolescents, and children aged
4 years or older.
Glucagon is a natural hormone produced by the pancreas. It works in
the opposite way to insulin and
raises blood sugar. It does this by converting stored sugar in the
liver called glycogen to glucose (a
form of sugar that the body uses for energy). The glucose then enters
the bloodstream and raises the
blood sugar level, so reducing the effects of hypoglycaemia.
You should always carry Baqsimi with you and tell your friends and
family that you are carrying it.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN BAQSIMI
_ _
IMPORTANT INFORMATION
If you are at risk of severe hypoglycaemia you should always have
Baqsimi readily available:
-
show your family members, friends, or people you work with where you
keep this medicine and
explain when and how to use it. Delay in treatment may be harmful
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Baqsimi 3 mg nasal powder in single-dose container
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single-dose container delivers nasal powder with 3 mg of
glucagon.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal powder in single-dose container (nasal powder).
White to practically white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Baqsimi is indicated for the treatment of severe hypoglycaemia in
adults, adolescents, and children
aged 4 years and over with diabetes mellitus.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults, adolescents and children aged 4 years and over _
The recommended dose is 3 mg glucagon administered into one nostril.
_Elderly _
(≥ 65 years)
_ _
No dose adjustment is required based on age.
Efficacy and safety data are very limited in patients aged 65 years
and absent in patients aged 75 and
above.
_ _
_Renal and hepatic impairment _
No dose adjustment is required based on renal and hepatic function.
_ _
_Paediatric population 0 - < 4 years _
The safety and efficacy of Baqsimi in infants and children aged 0 to <
4 years have not yet been
established. No data are available.
Method of administration
Nasal use only. Glucagon nasal powder is given in a single nostril.
Glucagon is passively absorbed
through the nasal mucosa. It is not necessary to inhale or breathe
deeply after dosing.
INSTRUCTIONS FOR ADMINISTERING GLUCAGON NASAL POWDER
1.
Remove the shrink wrap by pulling on the red stripe.
2.
Remove the single-dose container from the tube. Do not press the
plunger until ready to give the
dose.
3.
Hold the single-dose container between fingers and thumb. Do not test
before use as it contains
3
only one dose of glucagon and cannot be reused.
4.
Insert the tip of the single-dose container gently in one of the
nostrils until finger(s) touch the
outside of the nose.
5.
Push the plunger all the way in. The dose is complete when the green
line is no longer show
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kibulgaria 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kihispania 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kicheki 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kidenmaki 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kijerumani 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiestonia 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kigiriki 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kifaransa 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiitaliano 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kilatvia 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kilithuania 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kihungari 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kimalta 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiholanzi 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kipolandi 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kireno 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiromania 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kislovakia 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kislovenia 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kifinlandi 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiswidi 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 06-02-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kinorwe 05-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 05-07-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 05-07-2021
Tabia za bidhaa Tabia za bidhaa Kroeshia 05-07-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 06-02-2020

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati